Physician profile
Greg E Eudy
NPI 1154426872
$32,904.04
in general payments reported to CMS, 2019-2025
51 companies · $4,571 in 2025
The $4,571 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,292 · 2020: $3,744 · 2021: $4,533 · 2022: $4,892 · 2023: $5,473 · 2024: $5,400 · 2025: $4,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Consulting Fee: $400 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,817.61 |
| Consulting Fee | $400.00 |
| Education | $226.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,244.92 | 2019-2025 | |
| Amgen INC. | $4,519.89 | 2019-2025 | Enbrel, Evenity, Otezla |
| Pfizer INC. | $3,022.40 | 2019-2025 | |
| Ucb, INC. | $2,597.97 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $2,120.05 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Novartis Pharmaceuticals Corporation | $2,027.50 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,754.35 | 2019-2025 | Orencia, Sotyktu |
| Mallinckrodt Hospital Products INC. | $1,128.99 | 2020-2025 | Acthar |
| Glaxosmithkline, LLC. | $1,124.92 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals Lp | $1,010.21 | 2021-2025 | Saphnelo |
| Alexion Pharmaceuticals, INC. | $822.44 | 2019-2025 | Strensiq, Soliris |
| Radius Health, INC. | $741.59 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $698.35 | 2019-2024 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $696.16 | 2019-2025 | Ofev, Cyltezo |
| Sobi, INC | $500.56 | 2019-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Eudy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.